• Newly diagnosed AML, except for the APL subtype, according to the 2022 World Health Organization classification (WHO 2022 criteria)

• Age ≥18 years and ≤70 years

• Eligible for intensive chemotherapy

• No prior chemotherapy for AML except hydroxyurea for up to 14 days during the diagnostic screening phase for the control of peripheral leukemic blasts in patients with leukocytosis (e.g., white blood cell \[WBC\] counts\>25x10\^9/L)

• Eastern Cooperative Oncology Group (ECOG) performance status≤2

• Adequate renal function is defined as:

‣ Serum creatinine≤2.0×upper limit of normal (ULN)

⁃ Creatinine clearance (CrCl)\>30 mL/min calculated by the Cockcroft-Gault equation.

• Adequate hepatic and heart function is defined as:

‣ Serum total bilirubin≤1.5×ULN unless considered due to Gilbert's disease, or leukemic involvement

⁃ Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)≤2.5×ULN, unless considered due to leukemic involvement

⁃ Myocardial enzyme\<2.0×ULN

⁃ Left ventricular ejection fraction is within the normal range by measure of echocardiogram (ECHO)

• Signed a written informed consent form (ICF)

• Female participants who are of non-reproductive potential (i.e., post-menopausal by history of no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female participants of childbearing potential must have a negative serum pregnancy test upon study entry